An investigational new drug for bronchopulmonary dysplasia, called CF-MEV-132, has completed pre-clinical in-vivo testing. According to The Cell Factory, who are developing the drug, the potential treatment is now ready for testing in human clinical trials. To read about this news in more detail, click here to see The Cell Factory’s original press release at Globe Newswire.
About Bronchopulmonary Dysplasia
Bronchopulmonary dysplasia (BPD) is a type of chronic lung disease that can affect newborns and infants, particularly those who are born prematurely. Babies that are born prematurely may not have enough functional air sacs (alveoli) in the lungs, and they may need mechanical ventilation and oxygen to help them breathe. These treatments can save lives, but they may also cause lung damage that leads to BPD. It can scar the alveoli and may lead to long-term lung problems.
The drug CF-MEV-132, a type of anti-inflammatory EV, has been studied in pre-clinical research carried out by The Cell Factory and the University of Padova. Using rat models of BPD, the scientists found that the drug was safe and effective at reducing lung damage. The models were given intra-tracheal EVs. When the researchers analysed the lungs of the models, they found that those treated with the drug showed less organ injury than the controls. Compared to the controls, the treated group had a higher number of alveoli and a smaller alveolar volume. In addition, treatment with EVs was thought to have prevented a thickening of the small pulmonary vessels. You can find the published study here.
This potential drug is designed to reduce lung inflammation and to support the regeneration process in babies who have BPD. It’s intended to be used as a supplementary therapy, alongside other treatments such as oxygen, ventilation, and surfactant treatments.